Bicocca Open Archive

Logo unimib boa
SENNI, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 22.465
NA - Nord America 17.396
EU - Europa 11.149
SA - Sud America 3.204
AF - Africa 453
OC - Oceania 37
Continente sconosciuto - Info sul continente non disponibili 11
Totale 54.715
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.796
SG - Singapore 7.191
VN - Vietnam 5.005
HK - Hong Kong 3.985
IT - Italia 3.922
CN - Cina 2.958
BR - Brasile 2.438
RU - Federazione Russa 2.318
IE - Irlanda 1.343
CA - Canada 1.285
BD - Bangladesh 1.086
DE - Germania 910
SE - Svezia 608
FR - Francia 568
IN - India 451
AR - Argentina 325
GB - Regno Unito 309
FI - Finlandia 254
ID - Indonesia 244
KR - Corea 237
IQ - Iraq 188
MX - Messico 179
JP - Giappone 157
UA - Ucraina 151
AT - Austria 142
NL - Olanda 137
TR - Turchia 133
ZA - Sudafrica 120
EC - Ecuador 118
PK - Pakistan 118
ES - Italia 94
SA - Arabia Saudita 94
PH - Filippine 91
CO - Colombia 88
PL - Polonia 77
MY - Malesia 69
VE - Venezuela 66
UZ - Uzbekistan 59
MA - Marocco 58
TN - Tunisia 56
PY - Paraguay 54
BE - Belgio 47
CL - Cile 45
TH - Thailandia 44
JO - Giordania 41
AE - Emirati Arabi Uniti 38
EG - Egitto 38
KE - Kenya 35
ET - Etiopia 34
AU - Australia 29
UY - Uruguay 29
NP - Nepal 28
RO - Romania 28
DK - Danimarca 27
CR - Costa Rica 26
DZ - Algeria 26
IR - Iran 25
JM - Giamaica 25
KZ - Kazakistan 25
PE - Perù 25
CH - Svizzera 24
HU - Ungheria 22
PS - Palestinian Territory 22
LB - Libano 21
LT - Lituania 21
CZ - Repubblica Ceca 20
OM - Oman 19
IL - Israele 18
PT - Portogallo 18
NO - Norvegia 17
AZ - Azerbaigian 16
TW - Taiwan 16
RS - Serbia 15
HN - Honduras 13
NG - Nigeria 13
SY - Repubblica araba siriana 13
BO - Bolivia 12
GT - Guatemala 12
TT - Trinidad e Tobago 12
KG - Kirghizistan 11
AO - Angola 10
CI - Costa d'Avorio 10
GR - Grecia 10
NI - Nicaragua 10
QA - Qatar 10
SN - Senegal 10
LV - Lettonia 9
PA - Panama 9
AL - Albania 8
BG - Bulgaria 8
DO - Repubblica Dominicana 8
KW - Kuwait 8
NZ - Nuova Zelanda 8
SK - Slovacchia (Repubblica Slovacca) 8
BH - Bahrain 7
BW - Botswana 7
GE - Georgia 7
LK - Sri Lanka 7
MD - Moldavia 7
AM - Armenia 6
Totale 54.599
Salva come PNG Salva come JPEG
Città #
Hong Kong 3.929
Singapore 3.873
Ho Chi Minh City 1.572
Ashburn 1.438
San Jose 1.437
Dublin 1.295
Hanoi 1.228
Toronto 1.097
Milan 1.055
Chandler 807
New York 761
Princeton 746
Chicago 736
Hefei 602
The Dalles 591
Ann Arbor 578
Los Angeles 560
Frankfurt am Main 557
Santa Clara 464
Rome 449
Lauterbourg 430
Dallas 376
Beijing 346
Lawrence 291
Moscow 289
Fairfield 288
Altamura 268
Buffalo 254
Council Bluffs 239
Seoul 221
São Paulo 215
Helsinki 177
Boardman 161
Da Nang 158
Jakarta 157
Andover 147
Nuremberg 147
Wilmington 146
Haiphong 143
Seattle 139
Shanghai 121
Houston 120
San Diego 110
Cambridge 109
Woodbridge 102
Tokyo 96
Naples 95
Biên Hòa 92
Ha Long 91
Quận Bình Thạnh 91
Rio de Janeiro 91
Ninh Bình 90
Turin 86
London 77
Can Tho 75
Hải Dương 75
Baghdad 73
Guangzhou 68
Thái Nguyên 68
Figino 67
Vienna 66
Salt Lake City 65
Munich 64
Orem 62
Washington 62
Bắc Ninh 59
Montreal 59
Pune 59
Bắc Giang 53
Vũng Tàu 53
Mexico City 52
Brooklyn 51
Lappeenranta 51
Brasília 50
San Mateo 50
Warsaw 50
Bologna 49
Tashkent 49
Atlanta 48
Elk Grove Village 46
Phoenix 46
Belo Horizonte 45
Johannesburg 45
Dhaka 44
Brussels 43
Denver 43
Guayaquil 40
Quận Một 40
Buenos Aires 39
Istanbul 39
Riyadh 38
Kuala Lumpur 36
Amman 35
Curitiba 35
Quito 35
San Francisco 35
Charlotte 34
Jeddah 34
Lahore 34
Chennai 33
Totale 32.035
Salva come PNG Salva come JPEG
Nome #
Effect of Dapagliflozin on Accelerometer-Based Measures of Physical Activity in Patients With Heart Failure: An Analysis of the DETERMINE Trials 633
Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial 573
Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and mid-range ejection fraction 542
Discrepancy in the Diagnosis of Heart Failure with Preserved Ejection Fraction between Supine Versus Upright Exercise Hemodynamic Testing 502
Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes 499
Comparative effectiveness of sacubitril/valsartan versus angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in patients with de novo heart failure with mildly reduced and preserved ejection fraction 468
Machine learning for prediction of in-hospital mortality in coronavirus disease 2019 patients: Results from an Italian multicenter study 458
Early Initiation of Sacubitril/Valsartan in Patients With Acute Heart Failure and Renal Dysfunction: An Analysis of the TRANSITION Study 441
Exploring the Prognostic Performance of MECKI Score in Heart Failure Patients with Non-Valvular Atrial Fibrillation Treated with Edoxaban 441
Clinical presentation and outcome in a contemporary cohort of patients with acute myocarditis multicenter Lombardy registry 410
A matter of sex—persistent predictive value of MECKI score prognostic power in men and women with heart failure and reduced ejection fraction: a multicenter study 350
Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years 350
Impact of COVID-19 on exercise pathophysiology: a combined cardiopulmonary and echocardiographic exercise study 348
Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context 347
Coronary and total thoracic calcium scores predict mortality and provides pathophysiologic insights in COVID-19 patients 314
Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials 307
Prolonged QRS associated with left bundle branch conduction defect is a prognostic red flag in asymptomatic patients at risk for heart failure (ACCF/AHA stages A and B): Insights from the DAVID-Berg study 301
Strategy to identify subjects with diabetes mellitus more suitable for selective echocardiographic screening: The DAVID-Berg study 295
Frequency, characteristics, and outcome of patients with COVID-19 pneumonia and "silent hypoxemia" at admission: a severity-matched analysis 295
Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure 293
Haemodynamic characteristics of COVID-19 patients with acute respiratory distress syndrome requiring mechanical ventilation. An invasive assessment using right heart catheterization 287
Current Limitations of Invasive Exercise Hemodynamics for the Diagnosis of Heart Failure With Preserved Ejection Fraction 281
Pulmonary artery wedge pressure and left ventricular end-diastolic pressure during exercise in patients with dyspnoea 280
Is mild asymptomatic left ventricular systolic dysfunction always predictive of adverse events in high-risk populations? Insights from the DAVID-Berg study 277
Clonal hematopoiesis of indeterminate potential: implications for the cardiologists 263
Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial 261
Antecedent use of renin-angiotensin system inhibitors is associated with reduced mortality in elderly hypertensive Covid-19 patients 254
Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19 234
Right Heart Adaptation to Exercise in Pulmonary Hypertension: An Invasive Hemodynamic Study 231
Covid-19 and gender: lower rate but same mortality of severe disease in women-an observational study 231
Haemodynamic validation of the three-step HFA-PEFF algorithm to diagnose heart failure with preserved ejection fraction 223
Dose-dependent efficacy of β-blocker in patients with chronic heart failure and atrial fibrillation 220
Prevalence, Characteristics, and Outcomes of COVID-19-Associated Acute Myocarditis 214
Shedding Light on Latent Pulmonary Vascular Disease in Heart Failure With Preserved Ejection Fraction 212
Position paper ANMCO sull'utilizzo della terapia con sacubitril/valsartan nel paziente con scompenso cardiaco [ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure] 212
One-year mortality in COVID-19 is associated with patients’ comorbidities rather than pneumonia severity 209
Right ventricular reserve in cardiopulmonary disease: A simultaneous hemodynamic and three-dimensional echocardiographic study 209
An uncommon and challenging finding regarding the tricuspid valve: Case report, clinical considerations, and practical management 204
Characterization of compliance phenotypes in COVID-19 acute respiratory distress syndrome 203
Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis 199
Integrating natriuretic peptides and diastolic dysfunction to predict adverse events in high-risk asymptomatic subjects 198
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial 198
QRS fragmentation as possible new marker of fibrosis in patients with myocarditis. Preliminary validation with cardiac magnetic resonance 192
Patient adherence to drug treatment in a community based-sample of patients with chronic heart failure 192
Comorbidities, cardiovascular therapies, and COVID-19 mortality: A nationwide, italian observational study (ItaliCO) 191
The "Early Treatment" Approach Reducing Cardiovascular Risk in Patients with Type 2 Diabetes: A Consensus From an Expert Panel Using the Delphi Technique 190
The Therapy and Management of Heart Failure with Preserved Ejection Fraction: New Insights on Treatment 184
Grey zones on the use of new oral anticoagulants in atrial fibrillation. Expert opinion [Grey zones sull'uso dei nuovi anticoagulanti orali nella fibrillazione atriale. Opinioni degli esperti] 183
Erratum: Heart failure at the crossroads: Moving beyond blaming stakeholders to targeting the heart (Eur J Heart Fail (2015) 17:8 (760-763) doi:10.1002/ejhf.315)) 179
Finerenone Improves Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HF 175
Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials of Heart Failure and Chronic Kidney Disease 172
The chronic heart failure evolutions: Different fates and routes 172
Emergency surgery of acute coronary insufficiency [La chirurgia d'urgenza nell'insufficienza coronarica acuta.] 170
Role of continuous glucose monitoring in diabetic patients at high cardiovascular risk: an expert-based multidisciplinary Delphi consensus 169
COMPASS criteria applied to a contemporary cohort of unselected patients with stable coronary artery diseases: Insights from the STARTregistry 169
Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities 164
Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens 163
Position paper of the Italian Society of Cardiology: The renin-angiotensin-aldosterone system (RAAS) blockade in heart failure patients - Part I: From RAAS identification to clinical trials [Position paper della Società Italiana di Cardiologia: Il blocco del sistema renina-angiotensina-aldosterone (RAAS) nel paziente con scompenso cardiaco – Parte I: Dalla scoperta del RAAS ai trial clinici] 162
A 57-year-old man with rapidly progressive pulmonary hypertension 158
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC), with the special contribution of the Heart Failure Association (HFA) of the ESC 157
Exercise Right Ventricular-Pulmonary Arterial Coupling and Functional Outcome in Patients Undergoing Surgery for Secondary Ischemic Mitral Regurgitation 155
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC 154
Impact of clinical and subclinical coronary artery disease as assessed by coronary artery calcium in COVID-19 154
Prognostic Value of sST2 in Heart Failure 153
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction 150
Finerenone in Heart Failure with Improved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial 147
Hyperkalemia in chronic kidney disease patients with and without heart failure: an Italian economic modelling study 147
S Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction 147
Assistenza ventricolare sinistra dopo correzione combinata di stenosi valvolare aortica e coartazione istmica 147
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial 147
Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review 146
Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial 146
Rationale for and Practical Use of Sacubitril/Valsartan in the Patient's Journey with Heart Failure and Reduced Ejection Fraction 145
Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF 145
Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF 145
The risk of coronary artery disease after heart transplantation is increased in patients receiving low-dose cyclosporine, regardless of blood cyclosporine levels 144
OPTImal PHARMacological therapy for patients with heart failure: Rationale and design of the OPTIPHARM-HF registry 143
Vasopressors and inotropes in cardiogenic shock: Is there room for "adrenaline resuscitation"? 142
The follow-up of patients undergoing percutaneous coronary intervention: Potential impact of the application of a clinical pathway-structured management on the hospital-community integration and modulated on the patient's clinical risk 141
Heart failure with preserved ejection fraction: Update on diagnosis and therapy [Scompenso cardiaco con frazione di eiezione preservata: Update in tema di diagnosi e terapia] 140
Evolocumab and clinical outcomes in patients with cardiovascular disease 140
Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use 138
Multicenter Prospective Observational Study on Acute and Chronic Heart Failure One-Year Follow-up Results of IN-HF (Italian Network on Heart Failure) Outcome Registry 137
Bacterial Pericarditis due to Providencia stuartii An Atypical Case of Relapsing Pericarditis 136
Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial 134
Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome 134
An unusual case of cardiac aspergillosis 133
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity 132
Trattamento conservativo della valvola mitrale in presenza di endocardite infettiva 132
Tailored approach to trans-catheter palliation of critically reduced pulmonary blood supply. Data on long term follow up 130
Four aces of heart failure therapy: Systematic review of established and emerging therapies for heart failure with reduced ejection fraction 129
Preliminary results of intrathymic injection of donor cells to prevent acute rejection in human heart transplantation 129
Incidental cardiac aspergillomas in an immunocompromised woman 128
Cardiac contractility modulation in heart failure with reduced ejection fraction: critical review of evidence and application perspectives [Modulazione della contrattilità cardiaca nello scompenso cardiaco a frazione di eiezione ridotta: revisione critica delle evidenze ed aspetti decisionali pratici] 128
Finerenone and Atrial Fibrillation in Heart Failure A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial 127
Patiromer for Heart Failure Medication Optimization in Patients With Current or Past Hyperkalemia: DIAMOND Subanalysis 127
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial 126
Reduction of haemorrhagic complications during mechanically assisted circulation with the use of a multi-system anticoagulation protocol 124
Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study 124
TAVI in moderate aortic stenosis and heart failure: pros and cons 124
Totale 21.959
Salva come PNG Salva come JPEG
Categoria #
all - tutte 220.780
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 220.780
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.953 79 76 77 45 88 27 28 49 41 63 1.676 704
2022/20233.988 640 1.090 282 272 208 769 54 195 273 42 95 68
2023/20243.637 68 105 98 138 590 1.004 689 92 333 95 38 387
2024/202512.162 466 1.221 441 471 1.283 473 1.104 347 1.518 1.639 946 2.253
2025/202632.457 4.379 3.430 1.888 2.627 2.724 1.395 3.931 1.451 2.079 2.286 2.509 3.758
2026/2027131 131 0 0 0 0 0 0 0 0 0 0 0
Totale 56.437